Explore the words cloud of the PReDicT project. It provides you a very rough idea of what is the project "PReDicT" about.
The following table provides information about the project.
Coordinator |
P1VITAL LIMITED
Organization address contact info |
Coordinator Country | United Kingdom [UK] |
Project website | http://predictproject.p1vitalproducts.com/ |
Total cost | 4˙092˙630 € |
EC max contribution | 4˙092˙630 € (100%) |
Programme |
1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials) 2. H2020-EU.3.1.3. (Treating and managing disease) |
Code Call | H2020-SMEINST-2-2015 |
Funding Scheme | SME-2 |
Starting year | 2015 |
Duration (year-month-day) | from 2015-10-01 to 2019-11-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | P1VITAL LIMITED | UK (WALLINGFORD) | coordinator | 4˙092˙630.00 |
The objective of the Predicting Response to Depression Treatment (PReDicT) project is to conduct clinical, health economic and commercial research to validate the clinical performance and to complete the pre-commercial development of the P1vital PReDicT Test (formerly the eHealth P1vital® Oxford Emotional Test Battery (eH-ETB)), a novel medical device to improve the treatment and management of depression in clinical practice. On completion of the PReDicT project, the P1vital PReDicT Test will be ready for market launch. Depression is a common, serious and in some cases lifeâ€threatening condition, affecting around 350 million people in the world and 11% of EU citizens suffer from depression at some point in their life. It takes 4-6 weeks after starting antidepressant treatment before a physician can detect whether the treatment is working, the majority of patients with depression do not respond to the first treatment they are prescribed and it can take several months before an effective treatment is identified. During this time a patients’ ability to work and function socially is severely impaired, and they can spend many weeks or months absent from work placing a substantial burden on the economy and healthcare resources. The P1vital PReDicT Test addresses this problem by identifying within 1 week of starting treatment whether an antidepressant is working or not which can significantly reduce the time required to identify an effective treatment. Patients benefit from this by returning to good mental health sooner. The aggregated economic cost of depression in the EU is €92 billion, amounting to 1% of the total European gross domestic product. It is estimated that the P1vital PReDicT Test has the potential to reduce these healthcare and economic costs by more than 10%. Thus the PReDicT project focuses on a patient-centric, enabling technology that not only improves efficiency and outcomes for patients but also significantly reduces socio-economic costs.
Periodic and final reports | Documents, reports | 2020-03-24 10:20:27 |
Stakeholder reports (Assessment, Engagement and Impact) | Documents, reports | 2020-03-11 14:35:10 |
Quarterly project reports | Documents, reports | 2020-03-11 14:35:14 |
Communication of results (Publications, Conference presentations, Stakeholder meetings, Press releases) | Websites, patent fillings, videos etc. | 2020-03-11 14:35:01 |
Regular project newsletters | Websites, patent fillings, videos etc. | 2020-03-11 14:34:57 |
Clinical study reports of clinical effectiveness, cost effectiveness and clinical utility | Documents, reports | 2020-03-11 14:35:12 |
Publications submitted to peer reviewed journals | Documents, reports | 2020-03-11 14:35:14 |
Interim analysis report of Part A | Demonstrators, pilots, prototypes | 2019-09-06 09:01:49 |
Study protocol finalised and approved | Demonstrators, pilots, prototypes | 2019-09-06 09:01:49 |
Initial release of eH-ETB for use in WP2 clinical study | Other | 2019-09-06 09:01:49 |
Executive leadership team established. Project and financial reporting procedures agreed | Documents, reports | 2019-09-06 09:01:49 |
Country specific Ethics approvals obtained | Demonstrators, pilots, prototypes | 2019-09-06 09:01:49 |
Technical file updated, Self-declaration of conformity and registration of eH-ETB as a Class 1 medical device | Other | 2019-09-06 09:01:49 |
Supplemental release of the eH-ETB during WP2 clinical study | Other | 2019-09-06 09:01:49 |
Study agreements executed with health centres | Demonstrators, pilots, prototypes | 2019-09-06 09:01:49 |
Project website live | Websites, patent fillings, videos etc. | 2019-09-06 09:01:49 |
Take a look to the deliverables list in detail: detailed list of PReDicT deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2017 |
Jonathan Kingslake, Rebecca Dias, Gerard R. Dawson, Judit Simon, Guy M. Goodwin, Catherine J. Harmer, Richard Morriss, Susan Brown, Boliang Guo, Colin T. Dourish, Henricus G. Ruhé, Anne G. Lever, Dick J. Veltman, Anneke van Schaik, Jürgen Deckert, Andreas Reif, Michael Stäblein, Andreas Menke, Philip Gorwood, Géraldine Voegeli, Victor Pérez, Michael Browning The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial published pages: 558, ISSN: 1745-6215, DOI: 10.1186/s13063-017-2247-2 |
Trials 18/1 | 2019-09-06 |
2018 |
Browning, Michael Statistical Analysis Plan for the Predict Trial published pages: , ISSN: , DOI: 10.5281/zenodo.1235967 |
1 | 2019-09-06 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREDICT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PREDICT" are provided by the European Opendata Portal: CORDIS opendata.